Reuters: Regulatory News: Pfizer arthritis drug wins approval, ready to challenge Humira

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Pfizer arthritis drug wins approval, ready to challenge Humira Nov 6th 2012, 21:27 Tue Nov 6, 2012 4:27pm EST Nov 6 (Reuters) - U.S. regulators on Tuesday approved Pfizer Inc's Xeljanz treatment for rheumatoid arthritis, one of the company's most potentially lucrative experimental drugs, which is now poised to compete with Abbott Laboratories Inc's top-selling Humira. The U.S. Food and Drug Administration said in a release it had approved Pfizer's pill for patients with moderate to severe rheumatoid arthritis who have not benefited from or been able to tolerate the standard oral treatment, methotrexate. Industry analysts have predicted Pfizer's drug, better known by its chemical name tofacitinib, could garner annual peak sales of up to $3 billion. As a pill, it could prove more attractive to some patients than Abbott's $8 billion-a-year injectable Humira. Abbott has said the Pfizer drug poses no major competitive threat to its flagship product.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions